These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 18559722)
21. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649 [TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation. Atik E; Guray M; Gunesacar R; Ozgur T; Canda T Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099 [TBL] [Abstract][Full Text] [Related]
23. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1]. Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157 [TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921 [TBL] [Abstract][Full Text] [Related]
25. Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression. Stolf BS; Santos MM; Simao DF; Diaz JP; Cristo EB; Hirata R; Curado MP; Neves EJ; Kowalski LP; Carvalho AF Cancer; 2006 May; 106(9):1891-900. PubMed ID: 16565969 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597 [TBL] [Abstract][Full Text] [Related]
28. A PCR-based expression signature of malignancy in follicular thyroid tumors. Foukakis T; Gusnanto A; Au AY; Höög A; Lui WO; Larsson C; Wallin G; Zedenius J Endocr Relat Cancer; 2007 Jun; 14(2):381-91. PubMed ID: 17639052 [TBL] [Abstract][Full Text] [Related]
29. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. El Demellawy D; Nasr AL; Babay S; Alowami S Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015 [TBL] [Abstract][Full Text] [Related]
31. Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Aldred MA; Ginn-Pease ME; Morrison CD; Popkie AP; Gimm O; Hoang-Vu C; Krause U; Dralle H; Jhiang SM; Plass C; Eng C Cancer Res; 2003 Jun; 63(11):2864-71. PubMed ID: 12782592 [TBL] [Abstract][Full Text] [Related]
32. Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction. Taniguchi K; Takano T; Miyauchi A; Koizumi K; Ito Y; Takamura Y; Ishitobi M; Miyoshi Y; Taguchi T; Tamaki Y; Kato K; Noguchi S Oncology; 2005; 69(5):428-35. PubMed ID: 16319515 [TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis. Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390 [TBL] [Abstract][Full Text] [Related]
34. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Xu XC; el-Naggar AK; Lotan R Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193 [TBL] [Abstract][Full Text] [Related]
35. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Rosen J; He M; Umbricht C; Alexander HR; Dackiw AP; Zeiger MA; Libutti SK Surgery; 2005 Dec; 138(6):1050-6; discussion 1056-7. PubMed ID: 16360390 [TBL] [Abstract][Full Text] [Related]
36. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570 [TBL] [Abstract][Full Text] [Related]
37. p53 protein, PCNA staining, and DNA content in follicular neoplasms of the thyroid gland. Czyz W; Joensuu H; Pylkkänen L; Klemi PJ J Pathol; 1994 Dec; 174(4):267-74. PubMed ID: 7884588 [TBL] [Abstract][Full Text] [Related]
38. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. Weber F; Shen L; Aldred MA; Morrison CD; Frilling A; Saji M; Schuppert F; Broelsch CE; Ringel MD; Eng C J Clin Endocrinol Metab; 2005 May; 90(5):2512-21. PubMed ID: 15713710 [TBL] [Abstract][Full Text] [Related]
39. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms. Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948 [TBL] [Abstract][Full Text] [Related]